The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Millions of Americans on GLP-1 medications like semaglutide and tirzepatide are eating less and buying differently, and major retailers are starting to feel it. Learn what this shift means for your grocery habits, your nutrition needs, and how to make the most of your reduced appetite.
North Carolina's expected state budget will not restore GLP-1 weight-loss drug coverage for state employees, leaving thousands without insurance support for medications like Wegovy and Ozempic. This article breaks down what the coverage loss means financially, who is affected, and what practical steps you can take to manage costs or find alternatives.
Brazil has approved the first generic version of semaglutide, the active ingredient in Ozempic. While this approval does not immediately affect U.S. patients, it signals a major shift in the global GLP-1 landscape. Here's what it could mean for access and cost down the road.
The role of pharmacists in GLP-1 and peptide medicine is expanding fast, and that shift has real implications for how patients access, afford, and manage their medication. This article breaks down what the growing pharmacist role means for you, whether you're already on a GLP-1 or just starting to explore your options.
Eli Lilly continues to reinvest heavily in its GLP-1 portfolio, signaling major shifts in availability, competition, and pricing. For patients on or considering tirzepatide, these moves have real implications for cost and access. Here's what you need to know.
Millions of people on GLP-1 medications like Ozempic and Wegovy are losing significant weight, and the fashion industry is taking notice. Body size changes on these medications are real, rapid, and worth planning for. Here's what patients need to know about managing a shifting wardrobe and body image during GLP-1 treatment.
GLP-1 medications like semaglutide were designed for blood sugar and weight management, but researchers are now exploring their unexpected effects on addictive behaviors, including gambling. Early findings suggest these drugs may dampen reward-seeking in the brain. Here is what the current evidence actually shows and what it means for patients.
A recent observational study suggests that GLP-1 medications like Wegovy and Mounjaro may help curb cancer spread in people with obesity. While the research is early and not yet definitive, the findings add to a growing body of evidence about benefits beyond weight loss. Here's what patients need to know.
